Results 51 to 60 of about 222 (145)
Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper
ABSTRACT Over the past several decades, there have been significant advances in our understanding of both immunological and pharmacological mechanisms of adverse drug reactions (ADRs). Immune‐mediated drug reactions (IMDRs) represent a small proportion of ADRs and are caused by a pathological activation of the immune system or inflammatory pathways ...
Maria J. Torres +19 more
wiley +1 more source
Mitoxantrone and acquired Long-QT Syndrome. Case presentation.
The acquired Long-QT Syndrome can be caused by more than 100 non anti-arrhythmic drugs. These drugs block potassium channels; particularly the IKr which extends the ventricular repolarization beyond 450 ms.
Brandy Viera Valdés +1 more
doaj +2 more sources
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam +3 more
wiley +1 more source
Sleep-Associated Torsades de Pointes: A Case Report
Torsades de Pointes (TdP) is a polymorphic ventricular tachycardia that occurs in the presence of an acquired or congenital long QT syndrome (LQTS). We present the case of a 57 year-old man with end-stage renal disease on methadone maintenance in which ...
Guy Carmelli, Ian S. deSouza
doaj +1 more source
Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang +4 more
wiley +1 more source
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley +1 more source
ABSTRACT Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3‐ITD–positive AML.
Yuichiro Semba +21 more
wiley +1 more source
Acquired Long QT Syndrome and Torsade de Pointes Associated with HIV Infection
Here, we report the case of an HIV infected patient that was treated for pneumonia with a macrolid antibiotic. The patient experienced a prolongation of the already pathologic QTc interval resulting in repeated torsades de pointes necessitating CPR and ...
Alexander Shimabukuro-Vornhagen +7 more
doaj +1 more source
Resumen: La toxicidad por antimoniales puede comprometer múltiples sistemas y llega a ser potencialmente fatal. Se presenta el caso de un joven militar quien durante el tratamiento de su segundo episodio de leishmaniasis cutánea presentó toxicidad ...
Laura Arcos +3 more
doaj +1 more source
ABSTRACT Objective This study aimed to evaluate the feasibility and safety of venetoclax as a cytoreductive strategy during induction therapy in newly diagnosed acute promyelocytic leukemia (APL), and to provide an exploratory description of its early efficacy.
Yu Wang +3 more
wiley +1 more source

